JP2019112416A5 - - Google Patents

Download PDF

Info

Publication number
JP2019112416A5
JP2019112416A5 JP2019026073A JP2019026073A JP2019112416A5 JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5 JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019026073 A JP2019026073 A JP 2019026073A JP 2019112416 A5 JP2019112416 A5 JP 2019112416A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
exemestane
combination
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019026073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019112416A (ja
JP6860949B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019112416A publication Critical patent/JP2019112416A/ja
Publication of JP2019112416A5 publication Critical patent/JP2019112416A5/ja
Application granted granted Critical
Publication of JP6860949B2 publication Critical patent/JP6860949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019026073A 2013-05-03 2019-02-15 癌の処置方法 Active JP6860949B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016512076A Division JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Publications (3)

Publication Number Publication Date
JP2019112416A JP2019112416A (ja) 2019-07-11
JP2019112416A5 true JP2019112416A5 (OSRAM) 2019-09-19
JP6860949B2 JP6860949B2 (ja) 2021-04-21

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (OSRAM)
JP (2) JP2016522188A (OSRAM)
KR (1) KR102337598B1 (OSRAM)
CN (1) CN105492007A (OSRAM)
HK (1) HK1223547A1 (OSRAM)
WO (1) WO2014179738A1 (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016285597A1 (en) * 2015-06-29 2018-01-18 Syndax Pharmaceuticals, Inc. Combination of HDAC inhibitor and anti-PD-L1 antibody for treatment of cancer
US20190282541A1 (en) * 2016-07-20 2019-09-19 Eisai R&D Management Co., Ltd. Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
JP7537874B2 (ja) * 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ, インコーポレイテッド 併用療法
BR112020024762A2 (pt) * 2018-06-06 2021-03-23 Arena Pharmaceuticals, Inc. métodos de tratamento de condições relacionadas ao receptor s1p1
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150008926A (ko) * 2005-03-11 2015-01-23 더 리전츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코퍼레이트 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는 히스톤 데아세틸라제 억제제
US20080095843A1 (en) * 2006-07-11 2008-04-24 Nutalapati Siva R K Controlled-release formulations
WO2009067500A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac
TW200950783A (en) * 2008-03-07 2009-12-16 Pfizer Methods, dosage forms, and kits for administering ziprasidone without food
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
US10226472B2 (en) * 2011-09-02 2019-03-12 Syndax Pharmaceuticals, Inc. Methods for the treatment of breast cancer

Similar Documents

Publication Publication Date Title
JP2019112416A5 (OSRAM)
US9763898B2 (en) Nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease (IBD)
JP2019048843A5 (OSRAM)
JP2022121594A5 (OSRAM)
RU2022102537A (ru) Нейроактивные стероиды, их композиции и применения
JP2023107883A5 (OSRAM)
JP2023024704A (ja) 絶食条件下でのタシメルテオンの投与
JP2023153863A (ja) 15-hepeを含む組成物及びその使用方法
JP2014525465A5 (OSRAM)
JP2013529665A5 (OSRAM)
JP2016522188A5 (OSRAM)
RU2017112308A (ru) Композиции и способы для лечения бессонницы
JP2020532531A5 (OSRAM)
Mantovani Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
JP2017536380A (ja) 15−hepeを含む組成物、およびそれを用いて線維症を処置または防止する方法
WO2017148129A1 (zh) 一种用于治疗恶病质的药物组合物及其应用
JPWO2020210418A5 (OSRAM)
JP2019533672A5 (OSRAM)
JP2016539149A5 (OSRAM)
Jagmeet et al. Kanchanar guggulu and Varunadi kashaya in hypothyroidism-a case study
JP2018507880A5 (OSRAM)
RU2016136666A (ru) Составы на основе прогестерона
JP2020522568A5 (OSRAM)
JP2016514142A5 (OSRAM)
CN105050607A (zh) 用于治疗关节炎和骨关节炎的方法和组合物